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Abstract 
Background: Scratching in infants is considered to be related to early development of eczema. Little is known about 
the effects of maternal immune markers on scratching among infants. The objective is to compare the risks related to 
maternal serum immune markers (IMs) during pregnancy and IMs in breast milk for the occurrence of scratching in 
infants at 6 and 12 months of age.
Methods: Pregnant women were recruited in Columbia and Charleston, South Carolina. Blood (median 3 weeks 
prepartum) and breast milk (3 weeks postpartum) samples were collected. The concentrations of interferon (IFN)‑γ, 
IFN gamma‑induced protein 10 (IP‑10) (or CXCL10), CCL11, interleukin (IL) 1β, IL‑4, IL‑5, IL‑6, IL‑8 (CXCL8), IL‑10, IL‑12 
(p70), IL‑13, transforming growth factor (TGF)‑β1, and immunoglobulin (Ig) A in both maternal serum and whey were 
assayed using optimized immunoassays. Scratching and skin manifestations were ascertained at 6 and 12 months. 
Generalized estimating equations were used to estimate relative risks (RRs) of IMs for repeated measurements of 
scratching, considering intra‑individual correlations and adjusting for confounders.
Results: Of 178 women, 161 provided blood and 115 breast milk samples. IL‑1β, IL‑4, IL‑10, IL‑12, and CCL11 in mater‑
nal serum and whey were not analyzed due to a large proportion of non‑detectable values. Infants in the highest 
tertile of IL‑6 and IL‑13 in maternal serum were at higher risk of scratching (RR 1.73 and 1.84, respectively; p ≤ 0.002) 
compared to infants in the first tertile; similarly, infants born to mothers with high (versus low) levels of serum IL‑5 
were also at increased risk (RR 1.60, p = 0.002). None of the breast milk IMs studied were associated with scratching.
Conclusions: Scratching but not doctors diagnosed eczema was associated with higher levels of maternal IL‑5, IL‑6, 
and IL‑13 during pregnancy. Further investigations are necessary to determine how maternal serum IMs influence 
infants scratching.
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Background
Itching, also known as pruritus, is a symptom of a 
number of skin diseases including atopic dermatitis. 
It typically provokes scratching behavior with chronic 
scratching associated with high intensity of itching sen-
sations [1–3]. Besides atopic dermatitis, dry skin, non-
atopic eczema, non-atopic dermatitis, hives, ureamic 
kidney disorders (e.g. uremic pruritus) and fungal 
skin infections are typical causes that trigger itching/
scratching behavior. Although it is well-known that the 
sensation of itch can be mediated by histamine, which 
is synthesized and stored in mast cells, non-histamine 
pathways have also been identified [1–3]. Recent ele-
gant studies demonstrate the complex interplay of 
keratinocytes, immune cells, and the neurons in itch/
scratching biology [4–7]. Multiple molecular media-
tors released by these cells are involved in the genera-
tion of itching sensation and the consequent scratching 
responses [3].
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Itching symptoms in infancy are associated with early 
development of eczema [8]. According to the 2007 
National Survey of Children’s Health, 12.2  % children 
under age 17  years have been diagnosed with eczema 
or any other kind of skin allergy. Interestingly among 
patients with eczema, 90 % experience the onset of skin 
disease prior to the age of 5 years [9]. The etiology of skin 
allergy in infancy remain unclear and the role of immune 
markers (IMs) of maternal origin in affecting them is 
controversial [10, 11]. However, little is known about the 
relationship between maternal serum vs breast milk IMs 
and infants scratching behaviour. In contrast to itching, 
which cannot be communicated by infants, scratching 
behavior is considered as a major observable symptom of 
eczema in infants [12].
The first environment of the fetus is the gestational 
environment created by its mother [13]. Outside the 
womb, exposure to the ‘maternal environment’ is con-
tinued through breastfeeding. The infants immune sys-
tem is immature at birth; it is generally thought that the 
newborn rapidly develops a more mature immune system 
when exposed to its new environment; and during this 
transition, maternal immune factors derived during ges-
tation and from breast milk are considered to play criti-
cal protective roles against infants disease susceptibility 
[13]. However, inconsistent results regarding the protec-
tive effect of breastfeeding on the development of eczema 
have been reported. Thus, whereas some studies report 
that breastfeeding appears to protect against eczema 
[14–16], others found increased risk [17–19], while some 
others found lack of significant association [20]. The 
main limitation of these studies is that they did not con-
trol for immune markers in breast milk.
Maternal blood and breast milk contain an array of 
immune markers, including immunoglobulins, anti-
microbial factors, immune modulators including 
cytokines such as interferons (IFN), interleukins (IL) and 
chemokines [21]. These factors are thought to strengthen 
the infant’s immune system to protect it from infectious 
diseases [22]. However, it has been proposed that these 
IMs may also influence the susceptibility for non-infec-
tious chronic conditions such as eczema symptoms [23]. 
Some IMs in breast milk (such as IgA, TGF-β1, IFN-γ) 
are consider to confer protection [24]. However, prenatal 
conditions should also be considered. Recently, we found 
that maternal serum and breast milk whey levels of IL-5 
and IL-13 are risk markers for asthma-like symptoms 
among children; whereas whey IgA and TGF-β1 were 
protective by diminishing the relative risk of asthma-like 
symptoms [25].
Itch can be transmitted by activation of unmyelinated 
chemonociceptors, which are followed by neuropeptide 
release (from sensory nerves or indirectly by stimulating 
mediators from mast cells or keratinocytes) [26]. These 
neuropeptides release the histamine (from mast cells or 
basophils), which provokes a local inflammation, and 
subsequently generate the sensation of itching [2, 26]. 
Other mediators include proteinases, interleukins, opi-
oids, serotonin, and vanilloid receptors [2].
Currently no previous studies have reported analyz-
ing the relationship of immune components in maternal 
blood serum and breast milk whey with the development 
of scratching behavior among infants, which is the focus 
of our study. To our knowledge, this is the only study 
exploring the role of maternal serum in addition to breast 
milk whey on scratching episodes in infants. Although 
the sensation of itching (pruritus) cannot be reported by 
infants, it is in considered as a criterion for atopic der-
matitis or eczema in infancy [27]. In this epidemiological 
study, we had to focus on observable outcomes. Hence, 
the primary outcome of this study was maternal obser-
vation of infant scratching. As a secondary outcome, 
we included physician reported eczema. We hypothe-
sized that children whose mothers have higher levels of 
Th2 IMs (IL-4, IL-5, IL-13, and CCL11) in both serum 
and breast milk whey are more like to exhibit scratch-
ing behavior during infancy. We report that scratch-
ing behavior but not doctors diagnosed eczema among 
infants was associated with higher levels of maternal 
serum but not breast milk IL-5, IL-6, and IL-13 cytokines.
Methods
Study design
This study was derived from two longitudinal studies, 
which were approved by the University of South Caro-
lina, the Medical University of South Carolina, and the 
Palmetto Health Institutional Review Boards for Human 
Subjects. All participants signed a written consent form 
either in English or Spanish.
Participants
Expecting mothers were enrolled between April 2008 and 
January 2010 in Columbia and Charleston, South Caro-
lina in obstetric clinics and prenatal classes. Eligibility 
criteria included (1) aged 18 years or older, (2) no chronic 
illness (diabetes, thyroid or adrenal disorders, or chronic 
infections), (3) planned to stay in the area for at least 
9  months, and (4) willingness to provide a breast milk 
sample 2 weeks after delivery.
Clinical data collection and outcome
Data collection was described elsewhere [25]. In brief, 
women took part in four telephone or in-person inter-
views: a core demographic and baseline interview 
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conducted before delivery, and three interviews at 
2 weeks, and 6 and 12 months after delivery, respectively. 
In the baseline interview, information was obtained 
about women’s race (African American, European Amer-
ican or other), maternal age, marital status, cigarette use 
prior to and since the beginning of pregnancy, whether 
cigarettes were smoked inside the home (categorized into 
yes vs no), education level (less than high school, some 
college, college graduate, or graduate school). In addition, 
maternal and paternal history of asthma, wheezing and 
whistling in the chest was obtained by asking: “Have you 
ever had asthma?” and “Have you ever had wheezing or 
whistling in the chest at any time in the past?” A history 
of allergic rhinitis was assessed by two questions: “Have 
you ever had hay fever?” and “Have you ever suffered—in 
the absence of a cold—from an itchy stuffy or runny nose 
and/or swollen, itchy eyes?” Eczema history was assessed 
by the question: “Have you ever had an itchy rash, which 
was coming and going for at least 6 months?”
The second interview was conducted 2–4  weeks after 
delivery to collect data on the specifics of delivery (spon-
taneous vaginal delivery, after induction vaginal delivery, 
Cesarean section), gestational age (weeks), maternal and 
household smoking during pregnancy period (yes, no), 
gender of the offspring, maternal use of antibiotics and 
acetaminophen during pregnancy, and history of vaginal 
infections/pelvic conditions during pregnancy. The date 
of delivery was used to define exposure to pollen in South 
Carolina [25].
The third and fourth interviews were based on the 
International Study of Asthma and Allergies in Child-
hood (ISAAC) questionnaire [28] and additionally 
ascertained scratching at ages 6 and 12  months. The 
recall period was restricted to the respective previous 
6 months. At ages 6 and/or 12 months scratching (dichot-
omized) was based on a positive answer to the following 
question: “How often has your child scratched his/her-
self in the last 6 months?” [options: almost always; very 
often; sometimes; never]. In addition we collected infor-
mation on a reported doctor’s diagnosis of eczema and 
eczema-like manifestations. A diagnosis of eczema was 
ascertained by using the question “In the last 6 months, 
was a doctor’s diagnosis made in your child of atopic der-
matitis or eczema?” Regarding other skin manifestations 
of the child in the last 6 months, the following question 
was asked: “Have you noticed one or more of the follow-
ing skin disorders in your child (1) cradle cap, (2) cheek-
eczema, (3) ear eczema, and (4) eczema at other sites of 
the body. In addition, the interview collected information 
on duration of breastfeeding (weeks) as well as informa-
tion on smoking in the house and pet exposure in the last 
6 months.
Blood and breast milk collection and sample preparation
Women were asked to provide one blood sample before 
delivery and one breast milk sample about 2 weeks after 
delivery. Ten milliliters of blood were taken by venipunc-
ture from each woman in the last trimester of pregnancy 
(range 0–13  weeks before delivery, median 3  weeks 
before delivery). All serum samples were collected in 
sterile tubes (BD Vacutainer®, 10  mL), and centrifuged 
within 1  h of collection at 3500 revolutions per minute 
(rpm) for 10 min (minutes) at 4 °C. The separated serum 
samples were stored at −20 °C then after 24 h were trans-
ferred to −80  °C where the samples were stored until 
needed for analysis.
All women followed a detailed breast milk collec-
tion protocol. Each participant expressed approximately 
15  mL of breast milk, on average 3  weeks after deliv-
ery (range 1–8 weeks), in the morning after putting the 
baby to breast using an electric breast pump provided 
by the study. All breast milk samples were collected in 
sterile plastic bottles (Medela 80  ml [2.7  oz]). Research 
staffs picked the breast milk sample up at the partici-
pant residence or a place of convenience. Within 1 h of 
collection, all samples were transferred to sterile centri-
fuges tubes and spun at 2900 rpm for 10 min at 4 °C. Fat 
was removed; centrifugation and fat removal steps were 
repeated until all fat was taken out. Finally, the cell pel-
let was removed. The isolated whey and serum were ali-
quoted and stored in a −80 °C freezer until preparation 
for immunoassays.
Immuno‑assay protocols
The concentrations of IL-1β, IL-4, IL-5, IL-6, IL-8 
(CXCL8), IL-10, IL-12 (p70), IL-13, CXCL10 (IP-10), 
CCL11 (eotaxin-1), and IFN-γ in both serum and whey 
were assayed using the Bioplex Protein Array system 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). This 
multiplexes system allows for the assessment of sev-
eral IMs in the same Bio-Rad custom-made bioplex pro 
human cytokine, chemokine, and growth factor multiplex 
plate. ELISAs (enzyme-linked immunosorbent assay) 
were used to determine concentrations of IgA (Immu-
nology Consultants Laboratory, Portland, OR, USA) and 
TGF-β1 (R&D Systems, Minneapolis, MN, USA). To acti-
vate latent TGF-β1 to immuno-reactive TGF-β1 detecta-
ble by the Quantikine TGF-β1 immunoassay, we followed 
the manufacture procedure. All assays were conducted 
according to the manufacturer’s kit instructions. Each 
sample, including standards and the blank, was assayed 
in duplicate.
A total of 15 multiplexes and ELISAs were performed 
to determine the concentration of the IMs in serum and 
whey. For each plate we determined the limit of detection 
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(LOD) by multiplying the standard deviation of the blank 
by three. Those samples that had concentrations below 
the detection limit were assigned a value corresponding 
to half the LOD.
Exposures
The exposures were IMs levels in maternal serum before 
delivery and in whey. The following eight IMs were 
assessed: T-helper type 1/pro-inflammatory cytokines/
chemokines (IFN-γ, CXCL10, IL-6, and CXCL8), 
T-helper type 2/pro-allergic cytokines (IL-5 and IL-13), 
T-regulatory/anti-inflammatory cytokine (TGF-β1) and 
IgA levels [25]. The concentrations were recorded in pg/
mL, except for IgA, which was measured in mg/mL. Due 
to their distributions, we categorized IL-6, CXCL8, IL-13, 
IgA, and TGF-β1 into tertiles (high, median vs low) and 
IL-5, IFN-γ, and CXCL10 in both serum and whey, which 
were dichotomized (high vs median and low). Either 
the rank procedure was used to group IMs into tertiles, 
or the IMs were dichotomized (low vs high). Hence the 
lower group contains a combination of low values, the 
imputed ½ LOD values and other lower values.
Data analysis
We ran separate analyses for maternal serum and breast 
milk IMs. Confounders controlled for in the statistical 
analyses included maternal characteristics such as race, age 
at pregnancy, marital status, smoking during pregnancy, 
household cigarette use at ages 6 and 12 months, maternal 
and paternal history of eczema, consumption of acetami-
nophen during pregnancy, and vaginal or urinary infections 
during pregnancy. Offspring confounders comprised of 
gender and season of birth. Of note, we did not control for 
breastfeeding duration since the IMs are intervening vari-
ables between breastfeeding and scratching (i.e., only those 
infants who are breastfed will receive IMs in breast milk).
Regarding repeated measurement of scratching at ages 
6 and 12 months, generalized estimating equations (GEE) 
were employed to determine the role of the maternal 
IMs. Adjusting for within-participant effects using the 
regular maximum likelihood method, we started with 
an unstructured covariance matrix, which requires the 
least amount of constraints. Other covariance matrices, 
including compound symmetry and autoregressive, were 
considered and most of the models presented the same 
QIC goodness of fit statistic [29].
A total of 16 adjusted models (eight for serum and 
eight whey markers) were run to analyze the effect of IMs 
on scratching. Initially, we considered analyzing serum 
and whey IMs in one model; however, this led to collin-
earity problems [30], since most of the IMs presented 
correlations above 0.5 (e.g., CXCL10 and CXCL8 in whey 
r2 = 0.67; p < 0.0001).
We may consider that immune markers (IMs) in 
whey (after delivery) may result from maternal immune 
responses indicated by immune markers in maternal 
serum measured earlier during pregnancy. In this case, 
IMs in whey are the consequence of IMs in serum. Hence, 
they are in the same pathway with IMwhey as intervening 
variable: IMserum → IMwhey → scratching. However, in 
regression models, it is not appropriate to include both 
serum IM and whey IM in the same model, since control-
ling for an intervening variable as a confounder would 
split the initial association between the risk factor and 
the outcome into two associations, destroying the poten-
tial pathway. For these reasons, we statistically analyzed 
IMs in serum and whey separately. Although whey IM 
did not gain statistical significance for scratching, they 
may gain importance in path-analytical models.
We detected that the IMs had non-linear relations with 
scratching. We tested for linearity by cross-tabulating 
groups with increasing immune marker levels with the out-
come. Allowing non-linear associations, we therefore ana-
lyzed five IMs by comparing risk ratio (RR) estimates for 
scratching, contrasting the upper tertiles with the lowest 
tertile (low concentration) as reference group (IL-6, CXCL8, 
IL-13, IgA, and TGF-β1). IL-5, IFN-γ, and CXCL10 in both 
serum and whey were dichotomized (high vs median and 
low). Also we assessed the use of quartiles; however, there 
were not enough observations per category due to the 
sample size. Since we ran 16 individual adjusted models, 
we applied false discovery rate (FDR) (p = 0.05) for serum 
and whey IMs to adjust for multiple testing and avoid false 
positive associations [31]. We estimated the 95 % confidence 
interval (CI) and also presented p-values to identify associa-
tions that survive penalizing for multiple testing.
All confounders were simultaneously entered as indi-
cator variables into the models. A backward elimina-
tion process was used to retain confounders in the final 
model: confounders were those variables which changed 
the effect of the main association by 10 % or more when 
adding this factor into the model. All statistical analyses 
were performed using SAS version 9.3.
Results
Of 178 women who participated, 161 provided maternal 
blood and 115 breast milk samples (98 provided both pre-
natal blood sample and breast milk sample). Most of the 
participants were well educated and European American 
(Table 1). Approximately 84 % of the mothers and fathers 
were living together (i.e., married and single, but living 
together). A history of maternal eczema was reported by 
8.8 %, a history of asthma by 27.7 %, and a history of rhini-
tis by 49.6 %. Of the mothers 5.9 % reported smoking dur-
ing pregnancy, and 44.1 % had vaginal or urinary infections 
during pregnancy. The average mother’s age was 30 years.
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At 6 months of age 72.8 % of the mothers reported that 
they observed their child scratching in the last 6 months 
and 66.7  % at age 12  months covering the period from 
7–12 months (Table 2). The prevalence of doctor’s diag-
nosis of eczema was lower: 22.6 % at age 6 months and 
25.5 % at 12 months.
In the first 6 months, any eczema at any location was 
reported by 33.8  % of the mothers, and in 35.3  % from 
month 7 to 12. Among specific eczema locations, cheek 
eczema was most prevalent. Also cradle cap was a preva-
lent skin symptom reported in children (29.9 %; p < 0.05). 
Regarding scratching, doctors diagnosis of eczema was 
not related to scratching in the first 6 months and weakly 
between 7 and 12 months (Table 3). Cradle cap showed 
the strongest association (25.0  %; p  <  0.05). Between 
Table 1 Characteristics of the participants who have infor-
mation on  child’s scratch status either  at 6 or 12  months 
(n = 140)
a Including urinary tract infection, vaginitis or vaginosis, genital warts, genital 
herpes, gonorrhea, syphilis, chlamydia, trichomoniasis, yeast infection, and 
group B Streptococcus infections
Variables n (%)
Maternal race
 African American (AA) 30 (21.7)
 European American or Other 108 (78.3)
Sex of the infant
 Male 70 (50.0)
Maternal smoking during pregnancy 8 (5.9)
Smoke 6 months after delivery 14 (10.6)
Smoke 12 months after delivery 15 (15.0)
History of parental allergy
 Asthma
  Mother 38 (27.7)
  Father 35 (21.21)
 Eczema
  Mother 12 (8.8)
  Father 6 (4.1)
 Rhinitis
  Mother 68 (49.6)
  Father 77 (46.7)
Marital status
 Married 97 (71.9)
 Other 1 (0.7)
 Single but living together 16 (11.9)
 Single 21 (15.6)
Pets 6 months after delivery 4 (3.0)
Pets 12 months after delivery 6 (5.9)
Season of child’s birth
 Fall 30 (22.1)
 Spring 30 (22.1)
 Summer 30 (22.1)
 Winter 46 (33.7)
Use of antibiotics during pregnancy 34 (19.1)
Vaginal/urinary infections during pregnancya 60 (44.1)
Method of delivery
 Spontaneous vaginal delivery 32 (41.0)
 After induction vaginal delivery 26 (33.3)
 Cesarean section 20 (25.6)
Fish intake during pregnancy 6 (7.6)
Education
 Less than high school 11 (8.0)
 Some college 33 (23.9)
 College graduate 45 (32.6)
 Graduate school 49 (35.5)
Tylenol intake during pregnancy 58 (41.4)
Mean (n; 5, 95 %)
Maternal age during pregnancy 29.9 (131; 19.7, 39.0)
Gestational age (weeks) 38.6 (135; 35.0, 41.0)
Table 2 Scratching episodes and other skin manifestation 






Scratching episodes 72.8 66.7
Doctor’s diagnosis of eczema 22.6 25.5
Eczema‑like symptoms 33.8 35.3
Cheek‑eczema 22.1 18.6
Eczema on other sites of the head 
and body
24.3 16.7
Ear eczema 5.9 9.8
Swollen lips 1.5 0
Sore nappy‑area 2.9 2.9
Cradle cap 21.3 16.7
Table 3 The associations of  reported scratching 
with reported eczema diagnosis at ages 6 months
* p < 0.05
#  p < 0.1
Reported scratching  















22.2 24.3 30.9# 14.7
Eczema‑like 
symptoms
35.4 29.7 41.2 23.5
Cheek  
eczema
23.3 18.9 23.5# 8.8
Ear eczema 6.1 5.4 14.7* 0
Eczema on 
other sites
24.2 24.3 16.2 17.7
Cradle cap 29.9* 0 25.0* 0
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7–12  months, reported scratching was associated with 
ear and cheek eczema.
Next, we assessed the associations between IMs in 
maternal serum and whey with repeated observations of 
scratching at ages 6 and 12 months controlling for con-
founders (Table  4). Infants exposed to higher levels of 
Th-2 cytokines (IL-5 and IL-13) and pro-inflammatory 
cytokine IL-6 in serum had a significantly higher rela-
tive risk for scratching (RR 1.73, 1.60, 1.84; respectively) 
(Table 4). A linear trend was observed for IL-6 and IL-13 
in serum on scratching in infants. After adjusting for 
multiple testing, no whey IM was statistically significant.
Regarding the covariates, maternal education, gesta-
tional age, parental history of rhinitis and asthma, pets, 
maternal antibiotics consumption, and mode of delivery 
were removed from the models because they were not con-
founding. Infants whose mothers were African American, 
were at higher risk for developing scratching episodes than 
children of a European American mother (RR 1.31; 95 % CI 
1.02, 1.68; p = 0.03). In addition, infants of single mothers 
were more at risk for developing scratching than infants of 
married mothers (RR 1.46; 95  % CI 1.04, 2.06; p =  0.02). 
Regarding infant sex, boys presented more scratching epi-
sodes than girls (RR 1.29; 95 % CI 1.02, 1.63; p = 0.02).
Discussion
This is the first study that simultaneously examines the 
effect of immune markers (IMs) in both maternal serum 
Table 4 Adjusted effects of IMs in maternal serum and in breast milk whey on mothers’ observation of scratching (1 = yes 
or 0 = no) at ages 6 and 12 months (n = 156 and 169 observations, respectively)
a IMs were categorized into tertiles levels using the lowest level as reference, except for IL‑5, IFN‑γ, and CXCL10 in both serum and whey, which were dichotomized 
(high vs median and low). All IMs in serum and whey were adjusted for child’s sex, maternal race and age, vaginal or urinary infections during pregnancy, parental 
history of eczema, consumption of acetaminophen during pregnancy, marital status, season of child’s birth, smoking during pregnancy, and household cigarette use 
at ages 6 and 12 months
b Maternal education, parental history of rhinitis and asthma, pets, gestational age, maternal antibiotics consumption, and mode of delivery were removed from the 
models because they were not confounding
c The overall effect of the level was statistically significant after applying a false discovery rate (adjusted p value <0.05)
IMs in maternal serum before delivery IMs in breast milk whey
Immune Markerb Levels RRa 95 % CI p valuec FDRc Levels RRa 95 % CI p valuec FDRc
T‑helper type 1/pro‑inflammatory cytokines/chemokines (pg/mL)
 INF‑γ ≥5.92 1.10 (0.88, 1.36) 0.37 0.52 ≥2.13 1.24 (0.94, 1.61) 0.11 0.41
Reference <5.92 Reference <2.13
 CXCL10 ≥202 1.28c (1.03, 1.58) 0.02 0.06 ≥338 0.88 (0.67, 1.17) 0.40 0.64
Reference <202 Reference <338
 IL‑6 ≥4.25 1.73c (1.28, 2.31) 0.0003 0.002 ≥2.12 0.91 (0.94, 1.43) 0.67 0.9
2.12–4.25 1.44 (1.05, 1.95) 0.02 0.06 2.12 1.28 (0.73, 2.24) 0.37 0.64
Reference <2.12 Reference <2.12
 CXCL8 ≥1.59 1.37c (0.99, 1.91) 0.05 0.06 ≥5.28 0.77 (0.48, 1.23) 0.28 0.13
0.81–1.59 1.22 (0.94, 1.61) 0.13 0.15 1.40–5.28 0.81 (0.52, 1.25) 0.36 0.93
Reference <0.81 Reference <1.40
T‑helper type 2/pro‑allergic cytokines/chemokines (pg/mL)
 IL‑5 ≥1.59 1.60c (1.24, 2.07) 0.0002 0.002 ≥0.46 1.22 (0.88, 1.69) 0.22 0.60
Reference <1.59 Reference <0.46
 IL‑13 ≥1.85 1.84c (1.46, 2.29) <0.0001 0.0001 ≥1.71 1.47 (1.06, 2.02) 0.01 0.13
0.13–1.85 1.30 (0.96, 1.75) 0.08 0.15 0.11–1.71 0.82 (0.57, 1.19) 0.31 0.63
Reference <0.13 Reference <0.11
T‑regulatory/anti‑inflammatory cytokines (pg/mL)
 TGF‑β1 ≥28,809.27 1.12 (0.70, 1.80) 0.61 0.73 ≥774.63 0.71 (0.48, 1.05) 0.09 0.41
16,430.59–28,809.27 0.82 (0.52, 1.29) 0.40 0.52 438.28–774.63 0.98 (0.73, 1.31) 0.91 0.93
Reference <16,430.59 Reference <436.28
Secretory immunoglobulin A (mg/mL)
 IgA ≥6.02 0.96 (0.65, 1.40) 0.83 0.88 ≥87.58 0.98 (0.66, 1.44) 0.93 0.93
4.06–6.02 0.97 (0.63, 1.46) 0.87 0.88 1.28–87.58 1.07 (0.76, 1.47) 0.71 0.90
Reference <4.07 Reference <1.28
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and breast milk whey on scratching episodes in infants at 
ages 6 and 12  months. We found that three IMs out of 
serveral markers studied in maternal serum were asso-
ciated with scratching in infants. Our results reveals 
an increase in the risk of scratching when infants (as 
fetuses) are exposed to high levels of IL-6, IL-5, and IL-13 
cytokines in maternal serum, but not in breast milk whey. 
Regarding confounders: maternal race, maternal marital 
status, and child’s sex were all linked to scratching.
The strengths of this study include the prospective 
design, the independent collection and analysis of clini-
cal data and maternal serum and breast milk IMs. Our 
study is one of few comparable studies with a sample 
size of 100 and more [13]. With regards to selection bias, 
participation in studies during pregnancy and infancy 
depends on volunteering and a high level of dedication 
to study requirements. We enrolled 231 women and 
received breast milk or blood samples from 178 partici-
pants (77.1 %). In addition, we used statistical techniques 
to control for potential confounders.
Also, since levels of IMs in whey may vary over time, 
we tested whether the immune mediators’ levels cor-
related with the interval of collection after birth. None 
of the IMs were correlated with the time of milk col-
lection, which is an agreement with a recent review on 
breast milk IMs [13]. Regarding the dates of maternal 
blood sample collection, most IMs except for IFN-γ were 
not correlated with the number of days of blood collec-
tion before delivery. Since IFN-γ was not associated with 
scratching, there was no need to control for the dates of 
maternal blood sample collection in the other explana-
tory models.
Some IMs were not included in the analysis due to a 
large proportion of non-detectable values. Different fac-
tors may have contributed to the lack of detection. These 
may include the handling and temperature the extracted 
breast milk was stored prior to the assay. Since breast 
milk may have been left at room temperature for about 
an hour after expression, proteases in breast milk may 
have degraded the IMs in whey. In addition, cytokines 
in breast milk may have been undetectable due to their 
short half lives.
A limitation of our study is that models for each IM 
were run independently. This approach has the draw-
backs missing possible interactions between IMs; how-
ever, models that included possible interactions would 
have required a much larger sample size to detect sig-
nificant effects. Also, if mutual adjustments were made 
for immune markers, correlations between the immune 
markers would have resulted in collinearity between vari-
ous IMs and thus would have produced biased risk esti-
mates. However, to adjust for multiple testing of various 
single IMs, the false discovery rate was used.
In addition to main effects, also an imbalance of Th1 
and Th2 immune markers in maternal serum and in 
breast milk whey may be considered as risk factors. 
However, regarding the sample size, our study was not 
designed to also assess ratios of immune markers as 
predictors of scratching episodes, only to investigate 
the main role of IMs in maternal serum and breast milk 
whey. Therefore we did not analyze whether an imbal-
ance of multiple pro-inflammatory and anti-inflamma-
tory IMs are related to scratching episodes. Analyses 
with inclusion of all ratios in the regression models can-
not be conducted with sufficient statistical power. Hence 
we recommend future studies with a larger sample size to 
address these associations.
T‑helper 2 or type 2 cytokines
Our results suggest that high levels of two Th-2 or type 
2 immune response markers (IL-5 and IL-13) in maternal 
systemic circulation (serum) were a risk for the occur-
rence of scratching in infants 6–12 months later. Th2 cells 
play a critical role in the pathogenesis of allergic diseases 
including atopic dermatitis [32]. The Th2 cells are criti-
cal players in allergy because: (1) IgE antibody responses 
are Th2 (i.e., IL-4) dependent; (2) IL-5 is critical player in 
eosinophilia; (3) IL-13 is critical in mucus production and 
also enhances IgE responses; (4) these cytokines can also 
be produced by mast cells, basophil and eosinophil that 
can result in positive feed-back enhancement of chronic 
allergic reactions such as atopic dermatitis [33]. Our novel 
findings that higher maternal circulating levels of IL-5 
and IL-13 cytokines enhances risk of scratching in infants 
reflects the possibility that such maternal environment 
conditions the fetus for a future disease phenotype upon 
delivery [23, 33, 34]. Prior investigations suggest that 
maternal cytokines play a role in the fetal programming, 
with a significant impact on fetal immune outcomes [34].
T‑helper‑1 or type 1 and pro‑inflammatory cytokines
IMs related to T helper 1 (Th1) or type 1 immune 
responses are linked to cell-mediated and phagocyte-
dependent protective responses and are generally consid-
ered as anti-allergic immune responses; it was surprising 
that we did not find a significant association of prototypic 
Th1 cytokine IFN-λ in the maternal circulation with pro-
tection from scratching among infants; however a type 1 
promoting chemokine, CXCL10 (or IP-10) showed weak 
association before FDR analysis (Table 4) [35, 36].
Recent studies have identified IL-31 and IL-33 as a criti-
cal pruritogenic cytokines in humans and in mice because 
over expression of IL-31 and IL-33 in the skin enhances 
pruritus and atopic dermatitis phenotypes in mice [5]; and 
atopic skin lesions in both humans and in mice express very 
high levels of these two cytokines [4]. Most importantly, 
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studies show that IL-33 positively interacts with IL-5 and 
IL-13 in exhibiting its pruritogenic function [5]. Here we 
report a significant relationship of maternal Th2 cytokines 
IL-5/IL-13 with infant scratching behavior. This suggest 
that future work is needed to evaluate whether maternal 
levels of pruritogenic cytokines IL-33 (and IL-31) could 
also be critical risk factors for infant scratching [4–6, 37].
We unexpectedly found that the prototypic pro-
inflammatory cytokine IL-6 in the maternal circulation 
was highly associated with scratching behavior among 
infants. Results of the repeated measurements suggest a 
risk for scratching 6–12  month later when the levels of 
IL-6 in maternal serum were higher. We showed that IL-6 
cytokine in serum correlate positively with type 2 mark-
ers (IL-13, IL-5) and negatively with TGF-β1 [25]. To 
the best of our knowledge, no studies have considered 
the effect of this combination of IMs in maternal serum 
on scratching episodes. Furthermore, IL-6 has not been 
reported to be a critical player in allergic disease in gen-
eral although a recent report has linked elevated cardiac 
IL-6 levels to tree nut induced systemic anaphylaxis for 
the first time in a mouse model [38]. Neverthess, IL-6 
is considered to modulate pruritus because of its pro-
inflammatory activity. For example, IL-6 levels were 
significantly higher in hemodialysis patients with ure-
mic pruritus, compared to hemodialysis patients with-
out uremic pruritus [2]. Further assessment is necessary 
to clarify the interrelation of IL-6 with proto-typic Th2 
cytokines such as IL-5 and IL-13 on scratching and the 
possibility that scratching is more than simply a Th2 
driven response.
Lack of association of infant scratching with breast milk 
immune markers
In contrast to maternal serum Th2 cytokines and IL-6 
that are linked to infant scratching behaviour in this 
study, no link with breastmilk IMs was found. This find-
ing was surprising, and suggests that the half life of breast 
milk IM’s makes their quantification in a study such as 
ours difficult, or that systemic immune markers do not 
always correlate with mucosal (breast) immune markers.
Associations between scratching and physician diagnosed 
eczema
There is a lack of agreement between reported scratching 
and reported doctor’s diagnosis of eczema but a strong 
association with cradle cap and weak associations with 
maternal observance of specific eczema location between 
7–12  months. It is possible that the observed scratch-
ing is a response to different etiologies. Other trigger-
ing factors modulating pruritus may include contact and 
aero allergens, microbial agents, food, exogenous irri-
tants, and endogenous factors [26]. However, maternal 
reported scratching can be considered as a more sensitive 
(but less specific) marker for childhood atopic dermatitis 
than physician diagnosed eczema. Further investigations 
are necessary to determine the agreement doctor’s diag-
nosed eczema and scratching episodes.
Conclusion
According to our findings, Th2 related IMs in maternal 
serum may predispose the child to develop scratching in 
infancy. Hence, this may suggest that the gestational envi-
ronment (IMs in maternal serum) to which the offspring 
is exposed in uterus, could contribute to the risk of devel-
oping immune-related conditions after birth; however 
further investigation is warranted. We identified that Th2 
maternal serum IMs are associated to scratching episodes 
in children of ages 6 and 12 months. Thus, our data pre-
dicts that high maternal serum levels of IL-6, IL-5, and 
IL-13 during gestation are IMs that pose a higher risk for 
scratching among infants. Future studies should include 
maternal serum immune markers as predictors of scratch-
ing. In addition, further investigations are necessary to 
determine how maternal cytokines influence scratching 
and how they are related to the recently described pruri-
togenic cytokines such as IL-31 and IL-33.
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